Cholesterol and Modifications of Cholesterol in Rheumatic Disorders

Inflammatory Diseases of Blood Vessels: Second Edition

Volumn , Issue , 2012, Pages 473-483

  Tervaert, Jan Willem Cohen ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti ox LDL antibodies; Cardiovascular mortality; Oxidized LDL; Premature atherosclerosis; Pro inflammatory HDL particles; Statin induced autoimmunity; Statin induced myopathy; Statins

Indexed keywords

EID: 84886199922     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118355244.ch43     Document Type: Chapter

References (41)

1. Nicholls SJ, Hazen SL. Myeloperoxidase, modified lipoproteins, and atherogenesis. J Lipid Res 2009; 50:S346-51.
2. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol 2011; 12:204-12.
3. van Leeuwen M, Gijbels MJ, Duijvestijn A, et al. Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR-/-mice. Arterioscler Thromb Vasc Biol 2008; 28:84-9.
4. Shao B, Oda MN, Oram JF, et al. Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 2010; 23:447-54.
5. Tervaert JW. Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis. Clin Exp Immunol 2009; 15:377-85.
6. Liuzzo G, Goronzy JJ, Yang H, et al. T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000; 101:2883-8.
7. Goronzy JJ, Fujii H, Weyand CM. Telomeres, immune aging and autoimmunity. Exp Gerontol 2006; 41:246-51.
8. van Halm VP, Peters MJ, Voskuyl AE, et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross sectional study. The CARRE investigation. Ann Rheum Dis 2009; 68:1395-400.
9. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003; 30:1196-202.
10. Edwards CJ, Syddall H, Goswami P, et al. The autoantibody rheumatoid factor may be an independent risk factor for ischaemic heart disease in men. Heart 2007; 10:1263-7.
11. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully axccount for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001; 44:2331-7.
12. Morgan MD, Turnbull J, Selamet U, et al. Increased incidence of cardiovascular events in patients with antineutrophil cytoplasmic antibody-associated vasculitides: a matched-pair cohort study. Arthritis Rheum 2009; 60:3493-500.
13. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52:402-11.
14. Holmqvist ME, Wedrén S, Jacobsson LT, et al. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish populationbased rheumatoid arthritis cohorts. Arthritis Rheum 2009; 60:2861-9.
15. Heinecke J. HDL and cardiovascular-disease risk-time for a new approach?. N Engl J Med 2011; 364:171.
16. Hahn BH, Grossman J, Ansell BJ, et al. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2008; 10:213.
17. Kontush A, Chapman MJ. Functonally defective highdensity lipoprotein: anewtherapeutic target at the crossroads of dyslipidemia, inflammation, and athersclerosis. Pharmacol Rev 2006; 58:342-74.
18. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-22.
19. McMahon M, Grossman J, FitzGerald J, et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006; 54:2541-9.
20. Kiss E, Seres I, Tarr T, et al. Reduced paraoxonase1 activity is a risk for atherosclerosuis in patients with systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1108:83-91.
21. Frosteg°ard J, Svenungsson E, Wu R, et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005; 52:192-200.
22. Bergheanu SC, Van Tol A, Dallinga-Thie GM, et al. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a lowHDL-cholesterol. CurrMed Res Opin 2007; 23:2235-40.
23. Lee AB, Godfrey T, Rowley KG, et al. Traditional risk factor assessment does not capture the extent of cardiovascular risk in systemic lupus erythematosus. Intern Med J 2006; 36:237-43.
24. Myasoedova E, Crownson CS, Kremers HM, et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010; 69:1310-4.
25. Donahoo WT, Kosmiski LA, Eckel RH. Drugs causing dyslipoproteinemia. Endocrinol Metab Clin North Am 1998; 27:677-97.
26. Petri M, Perez-Gutthann S, Spence D, et al. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93:513-19.
27. Peters MJ, Vis M, Van Halm VP, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007; 66:958-61.
28. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Semin Arthritis Rheum 2009; 38:372-81.
29. AllisonAC. Mechanisms of action ofmycophenolatemofetil. Lupus 2005; 14(Suppl 1):S2-8.
30. Morris SJ, WaskoMC, Antohe JL. Hydroxychloroquine use is associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res 2010; 63:530-4.
31. Heeringa P, Tervaert JW. Role of oxidized low-density lipoprotein in renal disease. Curr Opin Nephrol Hypertens 2002; 11:287-93.
32. Van Leeuwen M, Damoiseaux J, Duijvestijn A, et al. The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis. Autoimmun Rev 2009; 9:53-7.
33. Gounopoulos P, Merki E, Hansen LF, et al. Antobodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. Minerva Cardioangiol 2007; 55:821-37.
34. Slot MC, Theunissen R, van Paassen P, et al. Anti-oxidized low-density lipoprotein antibodies in myeloperoxidase-positive vasculitis patients preferentially recognize hypochlorite-modified low density lipoproteins. Clin Exp Immunol 2007; 149:257-64.
35. Frostegard J. Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. Clin Immunol 2010; 134:47-54.
36. Rubenfire M, Brook RD, Rosenson RS. Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am J Med 2010; 123: 892-8.
37. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361:2113-22.
38. Balk EM, Lichtenstein AH, Chung M, et al. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. Atherosclerosis 2006; 189: 19-30.
39. Rosenson RS. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther 2008; 6:1319-30.
40. Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010; 33:171-87.
41. Chodic kG, Amatil H, Shalem Y, et al. Persistencewith statins and onset of rheumatoid arthritis: a population-based cohort study. PLoS Med 2010; 7:e1000336.